ArticleFrontiers in oncology2025
Spectrum of gynecologic malignancies in Northeastern Nigeria.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of female genital tract cancers in low-and middle-income countries (LIMC) is not yet well investigated. Although available studies are few, they are mainly based on single institutions. Here, four-year multi-institutional data on gynecologic cancers in northeastern Nigeria were examined to determine their distribution by age and subtype. Patient and Methods: This is a cross-sectional descriptive study using available data on histologically diagnosed gynecologic cancers archived in the pathology departments and/or cancer registries of six tertiary hospitals in northeastern Nigeria over four years. Alongside tumor type (according to site), patient age and presenting complaints were also documented. Descriptive statistics were used to present categorical variables as proportions, while quantitative variables of age were presented as medians. Results: A total of 863 gynecologic cancers were included in this study. The median age was 50 years (3 - 95 years) with a peak at 40 - 49 years. The uterine cervix was the most common site of cancer (66.6%, 575/863), while uterine corpus (15.5%, 134/863) and ovarian cancers (14.8%; 128/863) were nearly equal in proportion. Squamous cell cancer was the commonest histotype overall, while ovarian cancers had a preponderance of epithelial tumors in 67.9% (87/128) over sex cord stromal (12.5%; 16/128) and germ cell (9.4%, 12/128) tumors. The most common symptom was abnormal vaginal bleeding (38%) followed by abdominal swelling (21.1%) and foul-smelling vaginal discharge (14.1%). Population-based data also showed high parity among women in the region, ranging from 4 births to 7 births per woman in a reproductive lifetime (total fertility rate, TFR). Conclusion: The spectrum of cancers of the female genital tract in this study mirrors the population demographics characterized by a high proportion of young women in their reproductive age. Efforts to reduce the burden of this disease are urgently warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.